tafenoquine has been researched along with pyrimethamine in 7 studies
| Studies (tafenoquine) | Trials (tafenoquine) | Recent Studies (post-2010) (tafenoquine) | Studies (pyrimethamine) | Trials (pyrimethamine) | Recent Studies (post-2010) (pyrimethamine) |
|---|---|---|---|---|---|
| 186 | 37 | 113 | 5,088 | 738 | 1,047 |
| Protein | Taxonomy | tafenoquine (IC50) | pyrimethamine (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Homo sapiens (human) | 3.1057 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.1007 | |
| Beta-hexosaminidase subunit alpha | Homo sapiens (human) | 6.8333 | |
| Beta-hexosaminidase subunit beta | Homo sapiens (human) | 6.4 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 4.3 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.0609 | |
| Dihydrofolate reductase | Pneumocystis carinii | 3.25 | |
| Dihydrofolate reductase | Candida albicans | 5 | |
| Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) | 15.615 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.39 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.3217 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum 3D7 | 2.48 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 2.0727 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Queener, SF | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fidock, DA; Flannery, EL; Winzeler, EA | 1 |
| Avery, VM; Sykes, ML | 1 |
| Iyer, PS; Kannan, M; Khan, FR; Raichurkar, AV | 1 |
| Appiah, A; Hollingdale, MR; Li, J; Long, GW; McCutchan, TF; Milhous, WK; Zhu, JD | 1 |
| Baresel, PC; Campo, B; Magill, AJ; Ohrt, C; Rochford, R; Sampath, A; Tekwani, BL; Walker, LA | 1 |
3 review(s) available for tafenoquine and pyrimethamine
| Article | Year |
|---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |
Using genetic methods to define the targets of compounds with antimalarial activity.
Topics: Animals; Anopheles; Antimalarials; Drug Resistance; Genetic Association Studies; Genome, Protozoan; Humans; Malaria, Falciparum; Molecular Targeted Therapy; Plasmodium falciparum | 2013 |
Approaches to protozoan drug discovery: phenotypic screening.
Topics: Drug Discovery; Humans; Molecular Structure; Neglected Diseases; Phenotype; Plasmodium falciparum; Protozoan Infections; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma cruzi | 2013 |
4 other study(ies) available for tafenoquine and pyrimethamine
| Article | Year |
|---|---|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Falciparum; Molecular Docking Simulation; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2015 |
Plasmodium berghei: quantitation of in vitro effects of antimalarial drugs on exoerythrocytic development by a ribosomal RNA probe.
Topics: Aminoquinolines; Animals; Antimalarials; Base Sequence; Cells, Cultured; Liver; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Nucleic Acid Hybridization; Plasmodium berghei; Primaquine; Pyrimethamine; RNA Probes; RNA, Protozoan; RNA, Ribosomal | 1991 |
Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity.
Topics: Aminoquinolines; Anemia, Hemolytic; Animals; Antimalarials; Chloroquine; Combined Modality Therapy; Dapsone; Dose-Response Relationship, Drug; Doxycycline; Drug Evaluation, Preclinical; Erythrocyte Count; Erythrocyte Transfusion; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Mefloquine; Mice; Mice, Inbred NOD; Mice, SCID; Primaquine; Pyrimethamine; Reproducibility of Results; Sensitivity and Specificity; Transplantation, Heterologous | 2013 |